Trouble recruiting patients has thrown a wrench in the works of efforts to develop a novel prostate cancer treatment, EPI-7386.
Canadian prostate cancer specialist ESSA Pharma (Nasdaq: EPIX) has been working with Johnson & Johnson (NYSE: JNJ) to test the novel drug in combination with Erleada (apalutamide) or Zytiga (abiraterone acetate), plus prednisone.
ESSA, which retains all rights to EPI-7386 globally, believes the therapy could be used as a way to delay resistance to existing drugs used to treat prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze